Amgen Inc AMGN
Amgen Inc (Nasdaq: AMGN) is a cardio-renal-metabolic drug developer. Its lead program, Repatha (evolocumab), is marketed for Hypercholesterolemia / cardiovascular risk reduction.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Repatha | LDL-C lowering / MACE reduction | antibody | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved cardio-renal-metabolic companies
- ELI LILLY & Co LLY
- Amarin Corp Plc\uk AMRN
- Scienture Holdings, Inc. SCNX
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.